Lymphohistiocytoid

Lymphohistiocytoid mesothelioma is a rare variant of malignant mesothelioma in which the tumor is heavily infiltrated by inflammatory immune cells (lymphocytes and histiocytes) that can obscure the underlying cancer cells. Because the immune cells dominate the appearance under the microscope, this subtype is sometimes initially mistaken for lymphoma or a chronic inflammatory process. It is now classified as a subtype of sarcomatoid (or occasionally biphasic) mesothelioma, though some studies suggest it may have a somewhat better prognosis than typical sarcomatoid disease.

Origin

The term combines "lympho-" (lymphocytes), "histio-" (histiocytes, a type of tissue immune cell), and "-cytoid" (resembling cells). The variant was first described in pleural mesothelioma in 1988 by Henderson and colleagues, who recognized a distinct pattern dominated by inflammatory cells overlying malignant mesothelial tumor cells.

Significance in Asbestos Context

For patients, the key issue with lymphohistiocytoid mesothelioma is that it is easy to misdiagnose. Biopsies are often initially read as lymphoma, chronic pleuritis, or a reactive inflammatory process, which can delay correct treatment and accurate documentation of an asbestos-related cancer. Confirming the diagnosis usually requires expert pathology review and a panel of immunohistochemistry stains (such as calretinin, WT-1, cytokeratin, D2-40) to demonstrate the underlying mesothelial origin of the tumor cells hidden among the immune infiltrate. Because this variant is rare and tied to asbestos exposure like other mesotheliomas, accurate subtyping in the pathology report directly affects treatment planning, prognosis discussions, and the medical evidence supporting a legal claim.

Example Sentence

After her initial biopsy was read as possible lymphoma, a second-opinion pathologist at a mesothelioma specialty center diagnosed lymphohistiocytoid mesothelioma, which changed both her treatment plan and the direction of her asbestos claim.

Related Terms

Sarcomatoid Mesothelioma, Biphasic Mesothelioma, Epithelioid Mesothelioma, Immunohistochemistry, Pleural Mesothelioma, Histopathology

Notes

• If your biopsy was initially called lymphoma, chronic pleuritis, or "inflammatory process" but you have known asbestos exposure or pleural thickening, ask for a second pathology opinion at a mesothelioma specialty center.
• Request that the pathology report explicitly state the mesothelioma subtype (epithelioid, sarcomatoid, biphasic, or lymphohistiocytoid) and list the immunohistochemistry stains used. This matters for both treatment and any legal claim.
• Preserve all biopsy slides and tissue blocks; they are essential for confirmatory testing and may be needed by experts retained in a legal case.
• Ask your oncologist whether your subtype affects eligibility for immunotherapy or clinical trials, since the heavy immune infiltrate in lymphohistiocytoid tumors has prompted interest in checkpoint-inhibitor approaches.